15,199 Shares in ResMed Inc. (NYSE:RMD) Acquired by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. acquired a new position in ResMed Inc. (NYSE:RMD) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 15,199 shares of the medical equipment provider’s stock, valued at approximately $1,855,000.

Other hedge funds have also modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of ResMed by 7.0% in the fourth quarter. Geode Capital Management LLC now owns 2,020,799 shares of the medical equipment provider’s stock valued at $229,741,000 after acquiring an additional 131,732 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in ResMed by 1.3% in the first quarter. Louisiana State Employees Retirement System now owns 7,600 shares of the medical equipment provider’s stock valued at $790,000 after purchasing an additional 100 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in ResMed by 3.0% in the first quarter. Nisa Investment Advisors LLC now owns 102,647 shares of the medical equipment provider’s stock valued at $10,672,000 after purchasing an additional 3,023 shares during the last quarter. IFM Investors Pty Ltd grew its stake in ResMed by 7.1% in the first quarter. IFM Investors Pty Ltd now owns 9,217 shares of the medical equipment provider’s stock valued at $958,000 after purchasing an additional 609 shares during the last quarter. Finally, Telos Capital Management Inc. grew its stake in ResMed by 7.7% in the first quarter. Telos Capital Management Inc. now owns 26,021 shares of the medical equipment provider’s stock valued at $2,705,000 after purchasing an additional 1,862 shares during the last quarter. 66.54% of the stock is owned by institutional investors and hedge funds.

In other news, CFO Brett Sandercock sold 3,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $112.34, for a total transaction of $337,020.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John P. Wareham sold 44,342 shares of the business’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $113.86, for a total value of $5,048,780.12. Following the sale, the director now owns 24,085 shares in the company, valued at approximately $2,742,318.10. The disclosure for this sale can be found here. Insiders have sold 114,237 shares of company stock worth $13,737,550 in the last 90 days. Insiders own 1.24% of the company’s stock.

RMD has been the topic of several analyst reports. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a research note on Monday, July 8th. ValuEngine upgraded ResMed from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Goldman Sachs Group upgraded ResMed from a “neutral” rating to a “buy” rating in a research note on Monday, July 29th. UBS Group upgraded ResMed from a “neutral” rating to a “buy” rating and lifted their target price for the company from $122.00 to $140.00 in a research note on Monday, July 29th. Finally, JPMorgan Chase & Co. upgraded ResMed from an “underweight” rating to a “neutral” rating and set a $95.00 target price on the stock in a research note on Thursday, April 18th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. ResMed has an average rating of “Buy” and a consensus price target of $121.50.

RMD traded up $1.85 on Friday, hitting $134.18. The company had a trading volume of 15,249 shares, compared to its average volume of 568,735. The stock has a fifty day moving average price of $126.38 and a 200-day moving average price of $111.26. ResMed Inc. has a 12-month low of $90.64 and a 12-month high of $135.45. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.43 and a current ratio of 2.06. The stock has a market capitalization of $19.39 billion, a price-to-earnings ratio of 36.86, a P/E/G ratio of 3.25 and a beta of 0.47.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, July 25th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.03. ResMed had a return on equity of 26.49% and a net margin of 15.52%. The company had revenue of $705.00 million for the quarter, compared to analyst estimates of $701.56 million. During the same quarter in the previous year, the firm earned $0.95 earnings per share. The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. Analysts forecast that ResMed Inc. will post 3.92 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 19th. Stockholders of record on Thursday, August 15th will be paid a dividend of $0.39 per share. This is a positive change from ResMed’s previous quarterly dividend of $0.37. The ex-dividend date is Wednesday, August 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 1.16%. ResMed’s payout ratio is presently 40.66%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Story: Understanding Market Liquidity

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.